CME: HIV Prevention: The Role of Pre-Exposure Prophylaxis (HIV-PrEP)
ACCREDITATION EXPIRED: September 23, 2021
Activity Description / Statement of Need:
In this online CME self-learning activity:
The development of antiretroviral therapy (ART) has had a dramatic impact on HIV-related morbidity and mortality. The use of ART in HIV-infected patients has been the core strategy to not only treat HIV but also prevent vertical HIV transmission. Antiretrovirals can be used for HIV prevention in patients who are not HIV-infected but are repeatedly exposed to HIV in a strategy termed pre-exposure prophylaxis (PrEP). Although the rationale for PrEP stems from successful HIV prevention in HIV exposed infants with the use of ART during labor, early post-partum period, and throughout breastfeeding, it has more recently applied to been applied to sexual transmission (e.g., people with multiple partners or HIV serodiscordant couples) and people who inject drugs illicitly with support from the literature. Because much of what comprises evidence and guidelines supporting PrEP has been published relatively recently and because healthcare professionals are oftentimes unable to keep up with the steady publishing of literature and evolution of clinical practice in a timely manner, continuing healthcare education activities in this area are warranted.
Target Audience:
The following healthcare professionals: infectious disease specialists, primary care physicians, and public health; physician assistants, nurse practitioners, nurses, and pharmacists who practice in infectious disease; and any other healthcare professionals with an interest in or who clinically encounter HIV.
Commercial Support Disclosure: This activity is supported by an educational grant from Gilead.
Learners may participate in this activity free of charge.
Release Date: September 23, 2019 -- Expiration Date: September 23, 2021
Faculty: Geeta Gupta, MD
Agenda
Introduction, disclosures
|
Epidemiology and prevalence of HIV including risk factors |
|
Define PrEP
|
|
Supporting data, recommendations for use, and limitations
Recommendations for use and limitations
Cost-effectiveness of PrEP versus cost of HIV acquisition Patient cases |
|
Summary, conclusions, and best practices review |
Learning Objectives
By the end of the session the participant will be able to:
- Define the role of pre-exposure prophylaxis (PrEP) including identification of high-risk patient populations for appropriate use
- Analyze the data that support the use of PrEP for the prevention of HIV infection and apply it to patient cases
- Assess the safety and efficacy of PrEP in the context of the medical literature and apply that knowledge to patient cases
- Describe recommendations for PrEP use and the limitations to PrEP, and apply them to patient cases
- Recall the economic impact of the widespread use of PrEP including benefits and limitations
Accreditation
ACCME Activity #201349111
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Geeta Gupta, MD, University of California, Irvine, has has received funding for research grants and/or advisory boards from Pfizer and ViiV.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This activity is supported by an educational grant from Gilead.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Human immunodeficiency virus (HIV): Updates in care for the primary care physician
Human Immunodeficiency Virus (HIV): Optimizing pharmacotherapeutic management strategies
Novel antimicrobials and infectious disease practice: Research updates from ID Week 2019
Updates in vaccine-preventable diseases: Meningococcal meningitis